<DOC>
	<DOCNO>NCT02722421</DOCNO>
	<brief_summary>The purpose study determine whether increase dose levonorgestrel subdermal contraceptive implant overcome detrimental drug-drug interaction efavirenz base antiretroviral therapy .</brief_summary>
	<brief_title>Pharmacologic Strategies Use Levonorgestrel Implant HIV-infected Women</brief_title>
	<detailed_description>The investigator research team recently demonstrate combined use efavirenz ( EFV ) base antiretroviral therapy ( ART ) , prefer first-line ART regimen low middle income country , levonorgestrel ( LNG ) -releasing implant one year reduce LNG plasma concentration approximately 50 % compare woman ART . Importantly , investigator also observe three unintended pregnancy ( 15 % ) investigator study group woman EFV-based ART plus LNG implant , contrast &lt; 1 % expect failure rate implant woman without drug interaction . This study determine increase dose LNG-releasing subdermal implant effectively overcome know pharmacokinetic interaction EFV- base ART . LNG pharmacokinetic result participant enrol dose escalation study ( n=28 ) compare HIV-infected Ugandan woman standard dose LNG without concomitant EFV-based ART .</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document indicate participant inform pertinent aspect study . 2 . Participants willing able comply schedule visit , treatment plan , laboratory test , study procedure . 3 . Women age 18 year 45 year 4 . Diagnosed HIV infection 5 . Desiring LNG subdermal implant contraceptive method 6 . Receiving EFVbased ART minimum 3 month prior screen 7 . Must agree concurrent highly effective nonhormonal contraception copper intrauterine device ( IUD ) , previously medically sterilize . 8 . Participants must negative urine pregnancy test entry report unprotected sex since last menstrual period last two week . 1 . HIV RNA &gt; 50 copies/mL screen visit 2 . Serum hemoglobin &lt; 10.0 g/dl 3 . Elevations serum level alanine transaminase ( ALT ) 5 time upper limit normal 4 . Elevations serum creatinine 2.5 time upper limit normal 5 . Use drug know contraindicate LNG EFV within 30 day study entry . Due dynamic nature drug interaction related ART , study team review concomitant medication screen base US Department Health Human Services drug interaction table . 6 . Currently pregnant postpartum &lt; 30 day study entry 7 . Concurrent use hormonal contraception ( Note : use form hormonal contraception permissible time study enrollment/insertion LNG implant . Transition form hormonal contraception LNG subdermal implant accommodate accord LNG product label ) 8 . For EFV group , participant determine ineligible IUD placement World Health Organization ( WHO ) Medical Eligibility Criteria Contraceptive Use 9 . If participation study put participant unacceptable risk base judgment study staff</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>efavirenz</keyword>
	<keyword>levonorgestrel</keyword>
	<keyword>contraceptive implant</keyword>
</DOC>